Cargando…
Effect of epidermal growth factor ointment on persistent epithelial defects of the cornea
BACKGROUND: Healthy corneal epithelium acts as a barrier against damage to the deeper structures in the eye. Failure in the mechanisms of corneal epithelization can lead to persistent epithelial defects of the cornea (PEDs) and can compromise its function. Epidermal growth factor (EGF) promotes the...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7160978/ https://www.ncbi.nlm.nih.gov/pubmed/32295556 http://dx.doi.org/10.1186/s12886-020-01408-x |
_version_ | 1783522862149140480 |
---|---|
author | Moon, Hyun Sik Li, Lan Yoon, Hyeon Jeong Ji, Yong Sok Yoon, Kyung Chul |
author_facet | Moon, Hyun Sik Li, Lan Yoon, Hyeon Jeong Ji, Yong Sok Yoon, Kyung Chul |
author_sort | Moon, Hyun Sik |
collection | PubMed |
description | BACKGROUND: Healthy corneal epithelium acts as a barrier against damage to the deeper structures in the eye. Failure in the mechanisms of corneal epithelization can lead to persistent epithelial defects of the cornea (PEDs) and can compromise its function. Epidermal growth factor (EGF) promotes the proliferation, migration, and differentiation of epithelial cells, endothelial cells, and fibroblasts during wound healing and may be beneficial in treating patients with PEDs. We, therefore, investigated the effect of EGF ointment on patients with PEDs. METHODS: Fifteen patients with PEDs refractory to conventional treatment were treated twice a day with EGF ointment. Patient demographics and comorbidities were noted. The epithelial healing time was determined along with the primary outcome measures in the areas of the epithelial defects, visual acuity, visual analog scale (VAS) scores, and esthesiometer scores 1 month and 2 months after treatment. RESULTS: Five eyes of herpetic keratitis (33.3%), 3 eyes of dry eye disease (20.0%), 3 eyes of bacterial keratitis (20.0%), 2 eyes of limbal stem cell deficiency (13.3%), 1 eye of diabetic neurotrophic keratitis (6.7%), and 1 eye of filamentary keratitis (6.7%) were associated with PEDs, respectively. Two months following treatment with EGF ointment, there was a reduction in the area of the epithelial defects (5.7 ± 3.9 to 0.1 ± 0.3 mm(2)) as well as a significant improvement in best-corrected visual acuity (0.9 ± 0.8 to 0.6 ± 0.5 LogMAR) and VAS scores (4.5 ± 1.2 to 2.5 ± 0.7) in 12 eyes (80%). Among these cases, the mean epithelial healing time was 5.5 ± 1.8 weeks. Amniotic membrane transplantation was performed on the remaining 3 (20.0%) patients that did not respond to EGF treatment. CONCLUSIONS: EGF ointment could reduce symptoms and promotes corneal epithelialization of refractory PEDs. It may, therefore, be well-tolerated and a potentially beneficial addition in the management of refractory PEDs. |
format | Online Article Text |
id | pubmed-7160978 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-71609782020-04-22 Effect of epidermal growth factor ointment on persistent epithelial defects of the cornea Moon, Hyun Sik Li, Lan Yoon, Hyeon Jeong Ji, Yong Sok Yoon, Kyung Chul BMC Ophthalmol Research Article BACKGROUND: Healthy corneal epithelium acts as a barrier against damage to the deeper structures in the eye. Failure in the mechanisms of corneal epithelization can lead to persistent epithelial defects of the cornea (PEDs) and can compromise its function. Epidermal growth factor (EGF) promotes the proliferation, migration, and differentiation of epithelial cells, endothelial cells, and fibroblasts during wound healing and may be beneficial in treating patients with PEDs. We, therefore, investigated the effect of EGF ointment on patients with PEDs. METHODS: Fifteen patients with PEDs refractory to conventional treatment were treated twice a day with EGF ointment. Patient demographics and comorbidities were noted. The epithelial healing time was determined along with the primary outcome measures in the areas of the epithelial defects, visual acuity, visual analog scale (VAS) scores, and esthesiometer scores 1 month and 2 months after treatment. RESULTS: Five eyes of herpetic keratitis (33.3%), 3 eyes of dry eye disease (20.0%), 3 eyes of bacterial keratitis (20.0%), 2 eyes of limbal stem cell deficiency (13.3%), 1 eye of diabetic neurotrophic keratitis (6.7%), and 1 eye of filamentary keratitis (6.7%) were associated with PEDs, respectively. Two months following treatment with EGF ointment, there was a reduction in the area of the epithelial defects (5.7 ± 3.9 to 0.1 ± 0.3 mm(2)) as well as a significant improvement in best-corrected visual acuity (0.9 ± 0.8 to 0.6 ± 0.5 LogMAR) and VAS scores (4.5 ± 1.2 to 2.5 ± 0.7) in 12 eyes (80%). Among these cases, the mean epithelial healing time was 5.5 ± 1.8 weeks. Amniotic membrane transplantation was performed on the remaining 3 (20.0%) patients that did not respond to EGF treatment. CONCLUSIONS: EGF ointment could reduce symptoms and promotes corneal epithelialization of refractory PEDs. It may, therefore, be well-tolerated and a potentially beneficial addition in the management of refractory PEDs. BioMed Central 2020-04-15 /pmc/articles/PMC7160978/ /pubmed/32295556 http://dx.doi.org/10.1186/s12886-020-01408-x Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Article Moon, Hyun Sik Li, Lan Yoon, Hyeon Jeong Ji, Yong Sok Yoon, Kyung Chul Effect of epidermal growth factor ointment on persistent epithelial defects of the cornea |
title | Effect of epidermal growth factor ointment on persistent epithelial defects of the cornea |
title_full | Effect of epidermal growth factor ointment on persistent epithelial defects of the cornea |
title_fullStr | Effect of epidermal growth factor ointment on persistent epithelial defects of the cornea |
title_full_unstemmed | Effect of epidermal growth factor ointment on persistent epithelial defects of the cornea |
title_short | Effect of epidermal growth factor ointment on persistent epithelial defects of the cornea |
title_sort | effect of epidermal growth factor ointment on persistent epithelial defects of the cornea |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7160978/ https://www.ncbi.nlm.nih.gov/pubmed/32295556 http://dx.doi.org/10.1186/s12886-020-01408-x |
work_keys_str_mv | AT moonhyunsik effectofepidermalgrowthfactorointmentonpersistentepithelialdefectsofthecornea AT lilan effectofepidermalgrowthfactorointmentonpersistentepithelialdefectsofthecornea AT yoonhyeonjeong effectofepidermalgrowthfactorointmentonpersistentepithelialdefectsofthecornea AT jiyongsok effectofepidermalgrowthfactorointmentonpersistentepithelialdefectsofthecornea AT yoonkyungchul effectofepidermalgrowthfactorointmentonpersistentepithelialdefectsofthecornea |